SCHEMBL243754

SCHEMBL243754

O=C(O)c1ccc(OCc2ccccc2)c(Cl)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 12/20 0.73
HPGD P15428 3/20 0.70
RXRA P19793 2/20 0.70
RXRB P28702 2/20 0.70
NPC1 O15118 3/20 0.69
RAB9A P51151 3/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
TP53 P04637 2/20 0.69
XBP1 P17861 2/20 0.69
MEN1 O00255 1/20 0.69
MITF O75030 1/20 0.69
NFKB1 P19838 1/20 0.69
NFKB2 Q00653 1/20 0.69
KMT2A Q03164 1/20 0.69
RELA Q04206 1/20 0.69
MAPT P10636 1/20 0.67
HTT P42858 1/20 0.67
HSD17B10 Q99714 1/20 0.67
RXRG P48443 1/20 0.63
PTGER1 P34995 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9647665 0.98 MRGPRX4 (0.71) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL8756076 0.89 MRGPRX4 (0.61) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL698500 0.88 MRGPRX4 (0.80) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL8768763 0.88 MRGPRX4 (0.78) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL38658646 0.88 MRGPRX4 (0.59) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL9659745 0.88 MRGPRX4 (0.59) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL1934576 0.88 HPGD (0.70) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL16584995 0.87 MRGPRX4 (0.58) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL8768764 0.87 MRGPRX4 (0.58) MRGPRX4HPGDRXRARXRBNPC1
SCHEMBL2705229 0.86 MRGPRX4 (0.65) MRGPRX4HPGDRXRARXRBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116836157-A Oxadiazole derivative and preparation method and application thereof 星希尔生物科技(上海)有限公司 2023-10-03 CN disclosed
WO-2023179366-A1 OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 星希尔生物科技(上海)有限公司 2023-09-28 WO disclosed
US-9994558-B2 Multicyclic compounds and methods of using same Karyopharm Therapeutics Inc. (US) 2018-06-12 US disclosed
US-9994558-B2 Multicyclic compounds and methods of using same Karyopharm Therapeutics Inc. (US) 2018-06-12 US disclosed
US-9994558-B2 Multicyclic compounds and methods of using same Karyopharm Therapeutics Inc. (US) 2018-06-12 US disclosed
CN-103059036-B Polymerizable chiral compound DIC株式会社 2017-06-06 CN disclosed
US-20170096417-A1 Multicyclic Compounds And Methods Of Using Same Karyopharm Therapeutics Inc. (US) 2017-04-06 US disclosed
US-20170096417-A1 Multicyclic Compounds And Methods Of Using Same Karyopharm Therapeutics Inc. (US) 2017-04-06 US disclosed
US-20170096417-A1 Multicyclic Compounds And Methods Of Using Same Karyopharm Therapeutics Inc. (US) 2017-04-06 US disclosed
WO-2015042414-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME Karyopharm Therapeutics Inc. (US) 2015-03-26 WO disclosed
US-5677112-A USING AN ANTHRACENE COMPOUND WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-14 US disclosed
EP-0635480-B1 Anthracene derivatives WAKO PURE CHEM IND LTD (JP) 1997-03-19 EP disclosed
US-5576359-A ANTHRACENE DERIVATIVE, SOLVENT, COMPOUND CONTAINING GLYCIDYL GROUPS WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1996-11-19 US disclosed
EP-0636941-B1 Deep ultraviolet absorbent and its use in pattern formation WAKO PURE CHEM IND LTD (JP) 1996-03-20 EP disclosed
US-5498748-A PHENOLIC CROSSLINKER FOR A POLYGLYCIDYL METHACRYLATE TO FORM A MATERIAL USED AS AN ANTIREFLECTION COATING FOR DEEP UV LIGHT SUCH AS KRF EXIMER LASERS IN SEMICONDUCTOR PHOTORESISTS WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1996-03-12 US disclosed
EP-0636941-A1 Deep ultraviolet absorbent and its use in pattern formation WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1995-02-01 EP disclosed
EP-0635480-A1 Anthracene derivatives WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1995-01-25 EP disclosed
EP-0321984-B1 MESOMORPHIC COMPOUND HAVING BETA-HYDROXYCARBOXYL GROUP AS CHIRAL SOURCE AND LIQUID CRYSTAL COMPOSITION MITSUBISHI RAYON CO., LTD. (JP) 1992-10-21 EP disclosed
US-4925591-A FERROELECTRIC MITSUBISHI RAYON CO., LTD. (JP) 1990-05-15 US disclosed
EP-0321984-A1 Mesomorphic compound having beta-hydroxycarboxyl group as chiral source and liquid crystal composition MITSUBISHI RAYON CO., LTD. (JP) 1989-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096417-A1 Multicyclic Compounds And Methods Of Using Same PAK4, PAK5, PAK1 MRGPRX4 1667/4885HPGD 2381/4885RXRA 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.